Annual Report 1998
ERA-EDTA Registry
Section A  Countries collecting individual patient data (included in ERA-EDTA registry database)

A.1 AFFILIATED REGISTRY INFORMATION
Table A.1.1 General population of the country/region and percent coverage of general population in 1998
Table A.1.2 Renal centres: total number of centres and number collaborating

A.2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 1
Table A.2.1 Incident counts and percentage, by age group and gender (at day 1)
Table A.2.2 Gender, mean and median age of incident patients (at day 1)
Table A.2.3 Incident rates per million population, by age group and gender (at day 1, unadjusted)
Table A.2.4 Incident rates per million population, by cause of renal failure (at day 1, unadjusted)
Table A.2.5 Incident rates per million population, by cause of renal failure (at day 1, adjusted for age and gender)

A.3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 90
Table A.3.1 Incident counts and percentage, by age group and gender (at day 90)
Table A.3.2 Gender, mean and median age of incident patients (at day 90)
Table A.3.3 Incident rates per million population, by age group and gender (at day 90, unadjusted)
Table A.3.4 Incident rates per million population, by cause of renal failure (at day 90, unadjusted)
Table A.3.5 Incident rates per million population, by cause of renal failure (at day 90, adjusted for age and gender)
Table A.3.6 Incident counts, by established therapy (at day 90)
Table A.3.7 Incident rates per million population, by established therapy (at day 90, unadjusted)
Table A.3.8 Incident rates, by established therapy (at day 90, adjusted for age and gender)
Table A.3.9 Percentage of established therapy (at day 90, unadjusted)
Table A.3.10 Percentage of established therapy by age group, gender and diabetic status (at day 90, unadjusted)

A.4 PREVALENT PATIENTS ON RRT IN 1998 (residents only)
Table A.4.1 Prevalence counts and percentage, by age group and gender (patients alive on December 31)
Table A.4.2 Gender, mean and median age of prevalent patients (alive on December 31)
Table A.4.3 Prevalence per million population, by age group and gender (patients alive on December 31, unadjusted)
Table A.4.4 Prevalence per million population and percentage, by cause of renal failure (patients alive on December 31, unadjusted)
Table A.4.5 Prevalence per million population, by cause of renal failure (patients alive on December 31, adjusted for age and gender)
Table A.4.6 Prevalence counts, by established therapy (patients alive on December 31)
Table A.4.7 Prevalence per million population, by established therapy (patients alive on December 31, unadjusted)
Table A.4.8 Prevalence per million population, by established therapy (patients alive on December 31, adjusted for age and gender)
Table A.4.9 Percentage of established therapy (patients alive on December 31, unadjusted)
Table A.4.10 Percentage of established therapy by age group, gender and diabetic status (patients alive on December 31, unadjusted)
Table A.4.11 Patients living on a functioning graft (patients alive on December 31, unadjusted)

Section B  Countries collecting individual patient data, information via centre questionnaires or health authorities
(not included in ERA-EDTA registry database)

B.1 AFFILIATED REGISTRY INFORMATION
Table B.1.1 General population of the country/region by age group and gender, and percent coverage of the general population
Table B.1.2 Renal centres: total number of centres and number collaborating

B.2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 1
Table B.2.1 Incident counts and incident rates per million population (at day 1, unadjusted)
Table B.2.2 Gender, mean and median age of incident patients (at day 1)
Table B.2.3 Incident rates per million population (at day 1, adjusted for age and gender)

B.3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 90
Table B.3.1 Incident counts and incident rates per million population (at day 90, unadjusted)
Table B.3.2 Gender, mean and median age of incident patients (at day 90)
Table B.3.3 Incident rates per million population (at day 90, adjusted for age and gender)
Table B.3.4 Incident rates per million population and percentage, by cause of renal failure (at day 90, unadjusted)
Table B.3.5 Incident counts, by established therapy (at day 90)
Table B.3.6 Incident rates per million population, by established therapy (at day 90, unadjusted)
Table B.3.7 Percentage of established therapy (at day 90, unadjusted)

B.4 PREVALENT PATIENTS ON RRT ON DECEMBER 31, 1998 (residents only)
Table B.4.1 Prevalent counts and per million population (patients alive on December 31, unadjusted)
Table B.4.2 Gender, mean and median age of prevalent patients (alive on December 31)
Table B.4.3 Prevalence per million population (patients alive on December 31, adjusted for age and gender)
Table B.4.4  Prevalence per million population and percentage, by cause of renal failure1 (patients alive on December 31, unadjusted) ......................................................................................................................... 49
Table B.4.5  Prevalence counts, by established therapy (patients alive on December 31) .................................................................................................................. 50
Table B.4.6  Prevalence per million population, by established therapy (patients alive on December 31, unadjusted) 51
Table B.4.7  Percentage of established therapy (patients alive on December 31, unadjusted) ................................................................................. 52
Table B.4.8  Renal transplants, number and percentage by donor type .................................................................................................................. 53

Section C  Methods
General population base, patients and reference population for 1998 54
Databasis 56
Grouping of renal diseases 57
Introductory remarks

This is an annual report in progress. Countries will be added one by one.

Section A relates to the countries collecting individual patient data, which are included in the ERA Registry database. Their data will be published after receipt of the data sets, subsequent analysis by the Registry office and the formal permission for publication from the country involved.

Section B relates to the countries collecting individual patient data, information via centre questionnaires or health authorities (not included in the ERA Registry database). Their data will be published after they have returned the completed tables to the ERA Registry office.

Section C provides the methods used in section A and B, the grouping of renal diseases, and the dates of receipt of the data sets on which the analyses in section A are based.
### A.1 AFFILIATED REGISTRY INFORMATION

#### Table A.1.1 General population of the country/region and percent coverage of general population in 1998

<table>
<thead>
<tr>
<th>Country</th>
<th>General population in Thousands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>8013.6</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>5912.4</td>
</tr>
<tr>
<td>Greece</td>
<td>10516.4</td>
</tr>
<tr>
<td>Norway</td>
<td>4431.5</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>6104.9</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>15707.2</td>
</tr>
</tbody>
</table>
### Table A.1.2 Renal centres: total number of centres and number collaborating

<table>
<thead>
<tr>
<th>Country</th>
<th>Total number of renal centres</th>
<th>Number of renal centres collaborating with the registry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>61</td>
<td>61</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>29</td>
<td>29</td>
</tr>
<tr>
<td>Greece</td>
<td>105</td>
<td>105</td>
</tr>
<tr>
<td>Norway</td>
<td>19</td>
<td>19</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>51</td>
<td>51</td>
</tr>
</tbody>
</table>
### A.2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 1

**Table A.2.1 Incident counts and percentage, by age group and gender (at day 1)**

<table>
<thead>
<tr>
<th>Country</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Austria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>588</td>
<td>100</td>
<td>9</td>
</tr>
<tr>
<td>Women</td>
<td>416</td>
<td>100</td>
<td>5</td>
</tr>
<tr>
<td>All</td>
<td>1004</td>
<td>100</td>
<td>14</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>456</td>
<td>100</td>
<td>5</td>
</tr>
<tr>
<td>Women</td>
<td>362</td>
<td>100</td>
<td>3</td>
</tr>
<tr>
<td>All</td>
<td>818</td>
<td>100</td>
<td>8</td>
</tr>
<tr>
<td>Greece</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>815</td>
<td>100</td>
<td>10</td>
</tr>
<tr>
<td>Women</td>
<td>441</td>
<td>100</td>
<td>6</td>
</tr>
<tr>
<td>All</td>
<td>1256</td>
<td>100</td>
<td>16</td>
</tr>
<tr>
<td>Norway</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>265</td>
<td>100</td>
<td>8</td>
</tr>
<tr>
<td>Women</td>
<td>136</td>
<td>100</td>
<td>6</td>
</tr>
<tr>
<td>All</td>
<td>401</td>
<td>100</td>
<td>14</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>494</td>
<td>100</td>
<td>5</td>
</tr>
<tr>
<td>Women</td>
<td>338</td>
<td>100</td>
<td>5</td>
</tr>
<tr>
<td>All</td>
<td>832</td>
<td>100</td>
<td>10</td>
</tr>
<tr>
<td>The Netherlands</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>897</td>
<td>100</td>
<td>22</td>
</tr>
<tr>
<td>Women</td>
<td>565</td>
<td>100</td>
<td>16</td>
</tr>
<tr>
<td>All</td>
<td>1462</td>
<td>100</td>
<td>38</td>
</tr>
</tbody>
</table>

* Percentages are row percentages

Categories may not add up to total or to 100% because of missing values
### Countries collecting individual patient data (included in ERA-EDTA registry database)  May 20, 2003

#### Table A.2.2 Gender, mean and median age of incident patients (at day 1)

<table>
<thead>
<tr>
<th>Country</th>
<th>Gender</th>
<th>%</th>
<th>Mean (Years) (SD)</th>
<th>Median (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Austria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>59</td>
<td>59.4 (15.4)</td>
<td>62.4</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>41</td>
<td>62.9 (15.5)</td>
<td>66.9</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>60.9 (15.5)</td>
<td>64.2</td>
<td></td>
</tr>
<tr>
<td><strong>Belgium, Dutch-speaking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>56</td>
<td>63.9 (15.1)</td>
<td>67.2</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>44</td>
<td>65.8 (14.4)</td>
<td>68.8</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>64.7 (14.8)</td>
<td>67.8</td>
<td></td>
</tr>
<tr>
<td><strong>Greece</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>65</td>
<td>61.5 (14.9)</td>
<td>65.1</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>35</td>
<td>61.3 (14.9)</td>
<td>64.7</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>61.4 (14.9)</td>
<td>65.0</td>
<td></td>
</tr>
<tr>
<td><strong>Norway</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>66</td>
<td>60.0 (16.7)</td>
<td>64.0</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>34</td>
<td>57.2 (19.9)</td>
<td>61.6</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>59.1 (17.9)</td>
<td>63.6</td>
<td></td>
</tr>
<tr>
<td><strong>Spain, Catalonia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>59</td>
<td>63.7 (15.0)</td>
<td>67.2</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>41</td>
<td>62.8 (16.8)</td>
<td>66.9</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>63.3 (15.7)</td>
<td>67.1</td>
<td></td>
</tr>
<tr>
<td><strong>The Netherlands</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>61</td>
<td>59.3 (16.7)</td>
<td>63.2</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>39</td>
<td>58.1 (16.9)</td>
<td>61.2</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>58.8 (16.8)</td>
<td>62.5</td>
<td></td>
</tr>
</tbody>
</table>
## Table A.2.3 Incident rates per million population, by age group and gender (at day 1, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>Men</th>
<th>0-19</th>
<th>20-44</th>
<th>45-64</th>
<th>65-74</th>
<th>75+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>151.6</td>
<td>9.5</td>
<td>61.2</td>
<td>243.5</td>
<td>665.4</td>
<td>388.7</td>
</tr>
<tr>
<td>Women</td>
<td>100.6</td>
<td>5.5</td>
<td>35.5</td>
<td>137.4</td>
<td>361.7</td>
<td>222.1</td>
</tr>
<tr>
<td>All</td>
<td>125.3</td>
<td>7.6</td>
<td>48.5</td>
<td>189.5</td>
<td>491.0</td>
<td>274.8</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>156.3</td>
<td>7.1</td>
<td>49.2</td>
<td>197.4</td>
<td>581.7</td>
<td>748.2</td>
</tr>
<tr>
<td>Women</td>
<td>120.8</td>
<td>4.4</td>
<td>32.1</td>
<td>145.0</td>
<td>406.8</td>
<td>390.2</td>
</tr>
<tr>
<td>All</td>
<td>138.4</td>
<td>5.8</td>
<td>40.8</td>
<td>171.3</td>
<td>487.1</td>
<td>518.6</td>
</tr>
<tr>
<td>Greece</td>
<td>157.2</td>
<td>8.2</td>
<td>57.8</td>
<td>220.4</td>
<td>572.2</td>
<td>409.8</td>
</tr>
<tr>
<td>Women</td>
<td>82.7</td>
<td>5.2</td>
<td>30.3</td>
<td>124.0</td>
<td>251.4</td>
<td>156.9</td>
</tr>
<tr>
<td>All</td>
<td>119.4</td>
<td>6.8</td>
<td>44.1</td>
<td>171.3</td>
<td>399.5</td>
<td>263.0</td>
</tr>
<tr>
<td>Norway</td>
<td>120.9</td>
<td>13.6</td>
<td>48.8</td>
<td>180.3</td>
<td>473.9</td>
<td>404.4</td>
</tr>
<tr>
<td>Women</td>
<td>60.7</td>
<td>10.8</td>
<td>43.1</td>
<td>75.6</td>
<td>171.8</td>
<td>124.4</td>
</tr>
<tr>
<td>All</td>
<td>90.5</td>
<td>12.2</td>
<td>46.0</td>
<td>128.4</td>
<td>311.6</td>
<td>227.3</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>165.6</td>
<td>7.7</td>
<td>42.7</td>
<td>220.7</td>
<td>622.4</td>
<td>709.6</td>
</tr>
<tr>
<td>Women</td>
<td>108.3</td>
<td>8.1</td>
<td>38.6</td>
<td>139.0</td>
<td>293.8</td>
<td>322.6</td>
</tr>
<tr>
<td>All</td>
<td>136.3</td>
<td>7.9</td>
<td>40.7</td>
<td>179.1</td>
<td>442.6</td>
<td>463.5</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>115.5</td>
<td>11.2</td>
<td>47.8</td>
<td>168.5</td>
<td>487.0</td>
<td>458.9</td>
</tr>
<tr>
<td>Women</td>
<td>71.2</td>
<td>8.6</td>
<td>33.1</td>
<td>110.0</td>
<td>247.7</td>
<td>141.0</td>
</tr>
<tr>
<td>All</td>
<td>93.1</td>
<td>9.9</td>
<td>40.6</td>
<td>139.5</td>
<td>356.3</td>
<td>250.5</td>
</tr>
</tbody>
</table>
### Table A.2.4 Incident rates per million population, by cause of renal failure (at day 1, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td>125.3</td>
<td>100</td>
<td>17.3</td>
<td>14</td>
<td>6.6</td>
<td>5</td>
<td>4.4</td>
<td>5</td>
<td>8.1</td>
<td>3</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>138.4</td>
<td>100</td>
<td>13.7</td>
<td>10</td>
<td>9.6</td>
<td>7</td>
<td>8.5</td>
<td>6</td>
<td>13.4</td>
<td>10</td>
</tr>
<tr>
<td>Greece</td>
<td>119.4</td>
<td>100</td>
<td>18.7</td>
<td>16</td>
<td>8.3</td>
<td>7</td>
<td>6.7</td>
<td>6</td>
<td>7.9</td>
<td>7</td>
</tr>
<tr>
<td>Norway</td>
<td>90.5</td>
<td>100</td>
<td>20.5</td>
<td>23</td>
<td>7.9</td>
<td>9</td>
<td>9.0</td>
<td>10</td>
<td>5.0</td>
<td>5</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>136.3</td>
<td>100</td>
<td>19.2</td>
<td>14</td>
<td>12.8</td>
<td>9</td>
<td>9.3</td>
<td>7</td>
<td>6.1</td>
<td>4</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>93.1</td>
<td>100</td>
<td>11.6</td>
<td>12</td>
<td>6.4</td>
<td>7</td>
<td>5.3</td>
<td>6</td>
<td>6.4</td>
<td>7</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown. Categories may not add up to total or to 100% because of missing values.
### Table A.2.5 Incident rates per million population, by cause of renal failure (at day 1, adjusted for age and gender)

<table>
<thead>
<tr>
<th>Cause of renal failure</th>
<th>ALL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td>129.3</td>
<td>17.8</td>
<td>6.7</td>
<td>4.4</td>
<td>7.9</td>
<td>30.9</td>
<td>38.8</td>
<td>8.7</td>
<td>11.9</td>
<td>26.0</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>136.7</td>
<td>13.2</td>
<td>9.7</td>
<td>8.2</td>
<td>12.8</td>
<td>17.3</td>
<td>30.1</td>
<td>11.4</td>
<td>19.2</td>
<td>30.5</td>
</tr>
<tr>
<td>Greece</td>
<td>113.1</td>
<td>17.7</td>
<td>8.1</td>
<td>6.4</td>
<td>7.7</td>
<td>15.2</td>
<td>22.9</td>
<td>7.9</td>
<td>3.1</td>
<td>9.8</td>
</tr>
<tr>
<td>Norway</td>
<td>97.0</td>
<td>22.5</td>
<td>8.1</td>
<td>9.8</td>
<td>5.0</td>
<td>4.7</td>
<td>9.7</td>
<td>19.7</td>
<td>2.0</td>
<td>21.8</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>132.4</td>
<td>18.8</td>
<td>12.0</td>
<td>9.2</td>
<td>6.0</td>
<td>19.4</td>
<td>25.4</td>
<td>14.0</td>
<td>11.2</td>
<td>13.3</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>101.6</td>
<td>12.1</td>
<td>6.9</td>
<td>5.4</td>
<td>6.4</td>
<td>9.0</td>
<td>15.4</td>
<td>11.2</td>
<td>10.2</td>
<td>19.2</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown.
### Section A  Countries collecting individual patient data (included in ERA-EDTA registry database)  May 20, 2003

#### A.3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 90

**Table A.3.1 Incident counts and percentage, by age group and gender (at day 90)**

<table>
<thead>
<tr>
<th>Country</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Austria</td>
<td>510</td>
<td>100</td>
<td>338</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>87</td>
<td>17</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>39</td>
<td>14</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>403</td>
<td>100</td>
<td>331</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>52</td>
<td>13</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>39</td>
<td>9</td>
</tr>
<tr>
<td>Greece</td>
<td>797</td>
<td>100</td>
<td>434</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>110</td>
<td>14</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>35</td>
<td>12</td>
</tr>
<tr>
<td>Norway</td>
<td>242</td>
<td>100</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>16</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>84</td>
<td>14</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>467</td>
<td>100</td>
<td>314</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>11</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>152</td>
<td>11</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>808</td>
<td>100</td>
<td>513</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>3</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>139</td>
<td>17</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>294</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>221</td>
<td>37</td>
</tr>
</tbody>
</table>

Percentages are row percentages
Categories may not add up to total or to 100% because of missing values
### Table A.3.2 Gender, mean and median age of incident patients (at day 90)

<table>
<thead>
<tr>
<th>Gender, Region</th>
<th>Gender</th>
<th>%</th>
<th>Mean (Years)</th>
<th>(SD)</th>
<th>Median (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Austria</strong></td>
<td>Men</td>
<td>60</td>
<td>58.7</td>
<td>(15.6)</td>
<td>61.6</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>40</td>
<td>61.9</td>
<td>(15.8)</td>
<td>64.9</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>60.0</td>
<td>(15.7)</td>
<td>63.2</td>
</tr>
<tr>
<td><strong>Belgium, Dutch-speaking</strong></td>
<td>Men</td>
<td>55</td>
<td>63.7</td>
<td>(15.3)</td>
<td>67.3</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>45</td>
<td>65.6</td>
<td>(14.1)</td>
<td>68.2</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>64.6</td>
<td>(14.8)</td>
<td>67.8</td>
</tr>
<tr>
<td><strong>Greece</strong></td>
<td>Men</td>
<td>65</td>
<td>61.4</td>
<td>(14.9)</td>
<td>65.0</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>35</td>
<td>61.1</td>
<td>(14.9)</td>
<td>64.6</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>61.3</td>
<td>(14.9)</td>
<td>64.9</td>
</tr>
<tr>
<td><strong>Norway</strong></td>
<td>Men</td>
<td>65</td>
<td>59.7</td>
<td>(16.6)</td>
<td>63.4</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>35</td>
<td>56.2</td>
<td>(20.1)</td>
<td>60.2</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>58.5</td>
<td>(17.9)</td>
<td>62.8</td>
</tr>
<tr>
<td><strong>Spain, Catalonia</strong></td>
<td>Men</td>
<td>60</td>
<td>63.3</td>
<td>(15.0)</td>
<td>66.8</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>40</td>
<td>62.2</td>
<td>(16.5)</td>
<td>66.0</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>62.9</td>
<td>(15.6)</td>
<td>66.6</td>
</tr>
<tr>
<td><strong>The Netherlands</strong></td>
<td>Men</td>
<td>61</td>
<td>58.6</td>
<td>(17.0)</td>
<td>62.2</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>39</td>
<td>57.1</td>
<td>(17.1)</td>
<td>59.7</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>58.0</td>
<td>(17.0)</td>
<td>61.4</td>
</tr>
</tbody>
</table>
### Table A.3.3 Incident rates per million population, by age group and gender (at day 90, unadjusted)

<table>
<thead>
<tr>
<th>Country, Region</th>
<th>Gender</th>
<th>0-19</th>
<th>10-24</th>
<th>15-64</th>
<th>65-74</th>
<th>75+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td>Men</td>
<td>131.5</td>
<td>9.5</td>
<td>56.7</td>
<td>214.4</td>
<td>558.6</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>81.7</td>
<td>5.5</td>
<td>31.5</td>
<td>122.8</td>
<td>258.7</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>105.8</td>
<td>7.6</td>
<td>44.2</td>
<td>167.8</td>
<td>386.4</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>Men</td>
<td>138.2</td>
<td>5.6</td>
<td>47.4</td>
<td>169.2</td>
<td>505.7</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>110.5</td>
<td>3.0</td>
<td>29.3</td>
<td>137.9</td>
<td>374.5</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>124.1</td>
<td>4.3</td>
<td>38.5</td>
<td>153.6</td>
<td>434.7</td>
</tr>
<tr>
<td>Greece</td>
<td>Men</td>
<td>153.8</td>
<td>8.2</td>
<td>56.7</td>
<td>217.2</td>
<td>562.2</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>81.4</td>
<td>5.2</td>
<td>30.3</td>
<td>122.5</td>
<td>249.7</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>117.1</td>
<td>6.8</td>
<td>43.6</td>
<td>169.0</td>
<td>394.0</td>
</tr>
<tr>
<td>Norway</td>
<td>Men</td>
<td>110.4</td>
<td>11.9</td>
<td>47.6</td>
<td>168.2</td>
<td>405.3</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>57.2</td>
<td>10.8</td>
<td>43.1</td>
<td>71.5</td>
<td>155.7</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>83.5</td>
<td>11.4</td>
<td>45.4</td>
<td>120.3</td>
<td>271.2</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>Men</td>
<td>156.5</td>
<td>7.7</td>
<td>41.8</td>
<td>215.1</td>
<td>582.1</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>100.6</td>
<td>6.5</td>
<td>37.7</td>
<td>137.7</td>
<td>260.5</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>127.9</td>
<td>7.1</td>
<td>39.8</td>
<td>175.6</td>
<td>406.1</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>Men</td>
<td>104.0</td>
<td>11.2</td>
<td>45.5</td>
<td>155.3</td>
<td>409.2</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>64.6</td>
<td>8.6</td>
<td>32.5</td>
<td>103.5</td>
<td>215.4</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>84.1</td>
<td>9.9</td>
<td>39.1</td>
<td>129.7</td>
<td>303.4</td>
</tr>
</tbody>
</table>
### Table A.3.4 Incident rates per million population, by cause of renal failure (at day 90, unadjusted)

<table>
<thead>
<tr>
<th>Cause of renal failure</th>
<th>ALL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>%</td>
<td>PMP</td>
<td>%</td>
<td>PMP</td>
<td>%</td>
<td>PMP</td>
<td>%</td>
<td>PMP</td>
<td>%</td>
</tr>
<tr>
<td>Austria</td>
<td>105.8</td>
<td>100</td>
<td>16.5</td>
<td>16</td>
<td>5.7</td>
<td>5</td>
<td>4.2</td>
<td>4</td>
<td>7.5</td>
<td>7</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>124.1</td>
<td>100</td>
<td>12.7</td>
<td>10</td>
<td>8.8</td>
<td>7</td>
<td>8.3</td>
<td>7</td>
<td>12.0</td>
<td>10</td>
</tr>
<tr>
<td>Greece</td>
<td>117.1</td>
<td>100</td>
<td>18.5</td>
<td>16</td>
<td>8.0</td>
<td>7</td>
<td>6.6</td>
<td>6</td>
<td>7.8</td>
<td>7</td>
</tr>
<tr>
<td>Norway</td>
<td>83.5</td>
<td>100</td>
<td>19.2</td>
<td>23</td>
<td>7.2</td>
<td>9</td>
<td>8.8</td>
<td>11</td>
<td>4.7</td>
<td>6</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>127.9</td>
<td>100</td>
<td>18.3</td>
<td>14</td>
<td>12.3</td>
<td>10</td>
<td>9.3</td>
<td>7</td>
<td>5.7</td>
<td>4</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>84.1</td>
<td>100</td>
<td>11.1</td>
<td>13</td>
<td>6.0</td>
<td>7</td>
<td>5.3</td>
<td>6</td>
<td>6.1</td>
<td>7</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown. Categories may not add up to total or to 100% because of missing values.
### Table A.3.5 Incident rates per million population, by cause of renal failure (at day 90, adjusted for age and gender)

<table>
<thead>
<tr>
<th>Cause of renal failure</th>
<th>ALL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td>109.3</td>
<td>17.0</td>
<td>5.7</td>
<td>4.3</td>
<td>7.2</td>
<td>25.5</td>
<td>32.7</td>
<td>7.7</td>
<td>9.9</td>
<td>19.3</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>122.2</td>
<td>12.2</td>
<td>8.7</td>
<td>8.0</td>
<td>11.5</td>
<td>15.8</td>
<td>27.4</td>
<td>10.9</td>
<td>17.3</td>
<td>25.9</td>
</tr>
<tr>
<td>Greece</td>
<td>111.0</td>
<td>17.6</td>
<td>7.8</td>
<td>6.3</td>
<td>7.6</td>
<td>14.9</td>
<td>22.6</td>
<td>7.9</td>
<td>2.9</td>
<td>9.6</td>
</tr>
<tr>
<td>Norway</td>
<td>89.1</td>
<td>20.9</td>
<td>7.5</td>
<td>9.5</td>
<td>4.8</td>
<td>4.4</td>
<td>9.2</td>
<td>18.3</td>
<td>2.0</td>
<td>18.3</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>124.3</td>
<td>18.2</td>
<td>11.5</td>
<td>9.2</td>
<td>5.7</td>
<td>18.2</td>
<td>23.9</td>
<td>12.7</td>
<td>10.1</td>
<td>11.6</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>91.5</td>
<td>11.5</td>
<td>6.4</td>
<td>5.4</td>
<td>6.1</td>
<td>7.7</td>
<td>13.8</td>
<td>10.3</td>
<td>8.6</td>
<td>15.9</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown.
### Table A.3.6 Incident counts, by established therapy (at day 90)

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Austria</td>
<td>848</td>
<td>702</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>734</td>
<td>534</td>
<td>3</td>
<td>61</td>
<td>0</td>
<td>52</td>
</tr>
<tr>
<td>Greece</td>
<td>1231</td>
<td>1090</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>370</td>
<td>253</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>781</td>
<td>692</td>
<td>0</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>1321</td>
<td>813</td>
<td>1</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

*" is unavailable
### Table A.3.7 Incident rates per million population, by established therapy (at day 90, unadjusted)

<table>
<thead>
<tr>
<th></th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital Centre</td>
<td>Home</td>
<td>HD type unknown</td>
<td>Haemofiltration (HF)</td>
<td>Haemodiafiltration (HDF)</td>
<td>Total HD HF/HDF</td>
</tr>
<tr>
<td>Austria</td>
<td>105.8</td>
<td>87.6</td>
<td>0</td>
<td>0</td>
<td>0.2</td>
<td>4.5</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>124.1</td>
<td>90.3</td>
<td>0.5</td>
<td>10.3</td>
<td>0.2</td>
<td>8.8</td>
</tr>
<tr>
<td>Greece</td>
<td>117.1</td>
<td>103.6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>83.5</td>
<td>57.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.2</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>127.9</td>
<td>113.4</td>
<td>0</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>84.1</td>
<td>51.8</td>
<td>0.1</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

*" is unavailable
Table A.3.8 Incident rates, by established therapy (at day 90, adjusted for age and gender)

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Hospital</td>
<td>HD</td>
<td>PD</td>
<td>Living</td>
<td>Cadaveric</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Centre</td>
<td>type unknown</td>
<td>type unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td>109.3</td>
<td>90.5</td>
<td>0</td>
<td>0</td>
<td>0.3</td>
<td>4.6</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>122.2</td>
<td>89.2</td>
<td>0.5</td>
<td>10.3</td>
<td>0.2</td>
<td>8.3</td>
</tr>
<tr>
<td>Greece</td>
<td>111.0</td>
<td>98.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>89.1</td>
<td>60.5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.3</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>124.3</td>
<td>110.4</td>
<td>0</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>91.5</td>
<td>57.9</td>
<td>0.1</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

* is unavailable
### Section A  Countries collecting individual patient data (included in ERA-EDTA registry database)  

May 20, 2003

#### Table A.3.9  Percentage of established therapy (at day 90, unadjusted)

<table>
<thead>
<tr>
<th></th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Hospital</td>
<td>Centre</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Austria</td>
<td>100</td>
<td>83</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>100</td>
<td>73</td>
<td>0</td>
<td>8</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Greece</td>
<td>100</td>
<td>89</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>100</td>
<td>68</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>100</td>
<td>89</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>100</td>
<td>62</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Categories may not add up to total or to 100% because of missing values.
### Table A.3.10

Percentage of established therapy by age group, gender and diabetic status (at day 90, unadjusted)

<table>
<thead>
<tr>
<th></th>
<th>ALL</th>
<th>0-19</th>
<th>20-44</th>
<th>45-64</th>
<th>65-74</th>
<th>75+</th>
<th>Male</th>
<th>Female</th>
<th>Diabetes Mellitus</th>
<th>Non DM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HD</td>
<td>PD</td>
<td>TX</td>
<td>Oth</td>
<td>HD</td>
<td>PD</td>
<td>TX</td>
<td>Oth</td>
<td>HD</td>
<td>PD</td>
</tr>
<tr>
<td>Austria</td>
<td>83</td>
<td>10</td>
<td>3</td>
<td>4</td>
<td>29</td>
<td>21</td>
<td>4</td>
<td>3</td>
<td>80</td>
<td>11</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>81</td>
<td>11</td>
<td>0</td>
<td>7</td>
<td>67</td>
<td>33</td>
<td>0</td>
<td>0</td>
<td>64</td>
<td>29</td>
</tr>
<tr>
<td>Greece</td>
<td>91</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>38</td>
<td>13</td>
<td>0</td>
<td>90</td>
<td>9</td>
</tr>
<tr>
<td>Norway</td>
<td>68</td>
<td>17</td>
<td>15</td>
<td>0</td>
<td>46</td>
<td>0</td>
<td>54</td>
<td>0</td>
<td>48</td>
<td>26</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>89</td>
<td>10</td>
<td>2</td>
<td>0</td>
<td>44</td>
<td>22</td>
<td>33</td>
<td>0</td>
<td>83</td>
<td>13</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>62</td>
<td>36</td>
<td>3</td>
<td>0</td>
<td>42</td>
<td>50</td>
<td>8</td>
<td>0</td>
<td>41</td>
<td>52</td>
</tr>
</tbody>
</table>

Categories may not add up to total or to 100% because of missing values.
## A.4 PREVALENT PATIENTS ON RRT IN 1998 (RESIDENTS ONLY)

Table A.4.1 Prevalence counts and percentage, by age group and gender (patients alive on December 31)

<table>
<thead>
<tr>
<th>Country</th>
<th>Age Group</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td><strong>Austria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>3140</td>
<td>100</td>
<td>36</td>
<td>1</td>
<td>797</td>
<td>25</td>
<td>1419</td>
</tr>
<tr>
<td>Women</td>
<td>2180</td>
<td>100</td>
<td>54</td>
<td>2</td>
<td>544</td>
<td>25</td>
<td>845</td>
</tr>
<tr>
<td>All</td>
<td>5320</td>
<td>100</td>
<td>90</td>
<td>2</td>
<td>1341</td>
<td>25</td>
<td>2264</td>
</tr>
<tr>
<td><strong>Belgium, Dutch-speaking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>2323</td>
<td>100</td>
<td>46</td>
<td>2</td>
<td>457</td>
<td>20</td>
<td>932</td>
</tr>
<tr>
<td>Women</td>
<td>1971</td>
<td>100</td>
<td>29</td>
<td>1</td>
<td>302</td>
<td>15</td>
<td>728</td>
</tr>
<tr>
<td>All</td>
<td>4294</td>
<td>100</td>
<td>75</td>
<td>2</td>
<td>759</td>
<td>18</td>
<td>1660</td>
</tr>
<tr>
<td><strong>Greece</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>4588</td>
<td>100</td>
<td>61</td>
<td>1</td>
<td>937</td>
<td>20</td>
<td>1799</td>
</tr>
<tr>
<td>Women</td>
<td>2840</td>
<td>100</td>
<td>38</td>
<td>1</td>
<td>485</td>
<td>17</td>
<td>1096</td>
</tr>
<tr>
<td>All</td>
<td>7428</td>
<td>100</td>
<td>99</td>
<td>1</td>
<td>1422</td>
<td>19</td>
<td>2895</td>
</tr>
<tr>
<td><strong>Norway</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>1464</td>
<td>100</td>
<td>37</td>
<td>3</td>
<td>395</td>
<td>27</td>
<td>618</td>
</tr>
<tr>
<td>Women</td>
<td>843</td>
<td>100</td>
<td>24</td>
<td>3</td>
<td>267</td>
<td>32</td>
<td>348</td>
</tr>
<tr>
<td>All</td>
<td>2307</td>
<td>100</td>
<td>63</td>
<td>1</td>
<td>662</td>
<td>29</td>
<td>966</td>
</tr>
<tr>
<td><strong>Spain, Catalonia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>3425</td>
<td>100</td>
<td>42</td>
<td>1</td>
<td>737</td>
<td>22</td>
<td>1380</td>
</tr>
<tr>
<td>Women</td>
<td>2236</td>
<td>100</td>
<td>19</td>
<td>1</td>
<td>441</td>
<td>20</td>
<td>834</td>
</tr>
<tr>
<td>All</td>
<td>5661</td>
<td>100</td>
<td>61</td>
<td>1</td>
<td>1178</td>
<td>21</td>
<td>2214</td>
</tr>
<tr>
<td><strong>The Netherlands</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>5253</td>
<td>100</td>
<td>144</td>
<td>3</td>
<td>1476</td>
<td>28</td>
<td>2257</td>
</tr>
<tr>
<td>Women</td>
<td>3888</td>
<td>100</td>
<td>115</td>
<td>3</td>
<td>982</td>
<td>25</td>
<td>1656</td>
</tr>
<tr>
<td>All</td>
<td>9141</td>
<td>100</td>
<td>259</td>
<td>3</td>
<td>2458</td>
<td>27</td>
<td>3913</td>
</tr>
</tbody>
</table>

Percentages are row percentages.
### Table A.4.2 Gender, mean and median age of prevalent patients (alive on December 31)

<table>
<thead>
<tr>
<th>Region</th>
<th>Gender</th>
<th>%</th>
<th>Mean (Years)</th>
<th>SD</th>
<th>Median (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Austria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>59</td>
<td></td>
<td>54.8</td>
<td>14.9</td>
<td>56.7</td>
</tr>
<tr>
<td>Women</td>
<td>41</td>
<td></td>
<td>55.7</td>
<td>17.0</td>
<td>57.9</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td>55.2</td>
<td>15.8</td>
<td>57.2</td>
</tr>
<tr>
<td><strong>Belgium, Dutch-speaking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>54</td>
<td></td>
<td>57.7</td>
<td>16.2</td>
<td>59.7</td>
</tr>
<tr>
<td>Women</td>
<td>46</td>
<td></td>
<td>60.7</td>
<td>15.7</td>
<td>63.6</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td>59.1</td>
<td>16.1</td>
<td>61.8</td>
</tr>
<tr>
<td><strong>Greece</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>62</td>
<td></td>
<td>57.6</td>
<td>15.7</td>
<td>60.4</td>
</tr>
<tr>
<td>Women</td>
<td>38</td>
<td></td>
<td>58.9</td>
<td>15.5</td>
<td>62.1</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td>58.1</td>
<td>15.6</td>
<td>61.0</td>
</tr>
<tr>
<td><strong>Norway</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>63</td>
<td></td>
<td>53.8</td>
<td>16.2</td>
<td>54.4</td>
</tr>
<tr>
<td>Women</td>
<td>37</td>
<td></td>
<td>51.6</td>
<td>16.8</td>
<td>52.4</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td>53.0</td>
<td>16.5</td>
<td>53.6</td>
</tr>
<tr>
<td><strong>Spain, Catalonia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>61</td>
<td></td>
<td>57.2</td>
<td>15.9</td>
<td>59.0</td>
</tr>
<tr>
<td>Women</td>
<td>39</td>
<td></td>
<td>59.0</td>
<td>16.1</td>
<td>61.7</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td>57.9</td>
<td>16.0</td>
<td>60.3</td>
</tr>
<tr>
<td><strong>The Netherlands</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>57</td>
<td></td>
<td>53.0</td>
<td>16.4</td>
<td>53.4</td>
</tr>
<tr>
<td>Women</td>
<td>43</td>
<td></td>
<td>54.1</td>
<td>16.3</td>
<td>55.6</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td>53.5</td>
<td>16.4</td>
<td>54.4</td>
</tr>
</tbody>
</table>
Section A  Countries collecting individual patient data (included in ERA-EDTA registry database)  May 20, 2003

Table A.4.3  Prevalence per million population, by age group and gender (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Country, Language</th>
<th>ALL</th>
<th>0-19</th>
<th>20-44</th>
<th>45-64</th>
<th>65-74</th>
<th>75+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>809.8</td>
<td>38.0</td>
<td>519.1</td>
<td>1528.6</td>
<td>2419.5</td>
<td>1122.8</td>
</tr>
<tr>
<td>Women</td>
<td>527.0</td>
<td>59.9</td>
<td>364.1</td>
<td>879.3</td>
<td>1232.8</td>
<td>673.8</td>
</tr>
<tr>
<td>All</td>
<td>663.9</td>
<td>48.7</td>
<td>442.7</td>
<td>1198.3</td>
<td>1738.2</td>
<td>815.7</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>796.5</td>
<td>64.9</td>
<td>416.7</td>
<td>1314.0</td>
<td>2152.0</td>
<td>2316.4</td>
</tr>
<tr>
<td>Women</td>
<td>657.9</td>
<td>42.9</td>
<td>285.4</td>
<td>1035.0</td>
<td>1827.2</td>
<td>1392.0</td>
</tr>
<tr>
<td>All</td>
<td>726.3</td>
<td>54.2</td>
<td>352.2</td>
<td>1175.1</td>
<td>1976.4</td>
<td>1723.6</td>
</tr>
<tr>
<td>Greece</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>885.2</td>
<td>50.1</td>
<td>483.4</td>
<td>1447.4</td>
<td>2467.5</td>
<td>1744.4</td>
</tr>
<tr>
<td>Women</td>
<td>532.5</td>
<td>33.0</td>
<td>253.0</td>
<td>849.6</td>
<td>1463.7</td>
<td>842.6</td>
</tr>
<tr>
<td>All</td>
<td>706.3</td>
<td>41.8</td>
<td>368.8</td>
<td>1142.9</td>
<td>1927.1</td>
<td>1220.9</td>
</tr>
<tr>
<td>Norway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>667.8</td>
<td>63.1</td>
<td>481.6</td>
<td>1237.7</td>
<td>1590.2</td>
<td>1260.8</td>
</tr>
<tr>
<td>Women</td>
<td>376.5</td>
<td>43.1</td>
<td>338.2</td>
<td>710.8</td>
<td>714.0</td>
<td>327.0</td>
</tr>
<tr>
<td>All</td>
<td>520.6</td>
<td>53.4</td>
<td>411.3</td>
<td>976.9</td>
<td>1119.3</td>
<td>670.1</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>1147.8</td>
<td>64.5</td>
<td>616.8</td>
<td>1952.8</td>
<td>3071.7</td>
<td>2705.4</td>
</tr>
<tr>
<td>Women</td>
<td>716.4</td>
<td>30.9</td>
<td>378.0</td>
<td>1136.7</td>
<td>1747.7</td>
<td>1323.1</td>
</tr>
<tr>
<td>All</td>
<td>927.3</td>
<td>48.2</td>
<td>498.9</td>
<td>1537.1</td>
<td>2347.1</td>
<td>1826.2</td>
</tr>
<tr>
<td>The Netherlands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>676.4</td>
<td>73.6</td>
<td>482.8</td>
<td>1191.9</td>
<td>1681.2</td>
<td>1461.0</td>
</tr>
<tr>
<td>Women</td>
<td>489.6</td>
<td>61.5</td>
<td>332.0</td>
<td>893.0</td>
<td>1220.1</td>
<td>560.7</td>
</tr>
<tr>
<td>All</td>
<td>582.0</td>
<td>67.7</td>
<td>408.7</td>
<td>1044.0</td>
<td>1429.4</td>
<td>870.7</td>
</tr>
</tbody>
</table>
### Section A  Countries collecting individual patient data (included in ERA-EDTA registry database)

**May 20, 2003**

Table A.4.4  Prevalence per million population and percentage, by cause of renal failure (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Cause of renal failure</th>
<th>Type I</th>
<th>Type II</th>
<th>Both</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>% PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>ALL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>663.9</td>
<td>100</td>
<td>184.4</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>726.3</td>
<td>100</td>
<td>158.5</td>
</tr>
<tr>
<td>Greece</td>
<td>706.3</td>
<td>100</td>
<td>184.5</td>
</tr>
<tr>
<td>Norway</td>
<td>520.6</td>
<td>100</td>
<td>186.2</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>927.3</td>
<td>100</td>
<td>217.2</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>582.0</td>
<td>100</td>
<td>133.7</td>
</tr>
</tbody>
</table>

### Abbreviations used:
- GN: Glomerulonephritis/sclerosis
- PN: Pyelonephritis
- PKD: Polycystic kidneys, adult type
- DM: Diabetes mellitus
- HT: Hypertension
- RVD: Renal vascular disease
- Misc: Miscellaneous
- Unkn: Unknown

Categories may not add up to total or to 100% because of missing values.
Table A.4.5  Prevalence per million population, by cause of renal failure (patients alive on December 31, adjusted for age and gender)

<table>
<thead>
<tr>
<th>Cause of renal failure</th>
<th>ALL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Type II</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Both</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Austria</td>
<td>673.3</td>
<td>186.1</td>
<td>72.1</td>
<td>34.0</td>
<td>42.1</td>
<td>72.3</td>
<td>114.4</td>
<td>30.8</td>
<td>30.0</td>
<td>129.1</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>709.0</td>
<td>155.9</td>
<td>67.0</td>
<td>66.4</td>
<td>60.9</td>
<td>38.6</td>
<td>99.4</td>
<td>45.1</td>
<td>45.5</td>
<td>170.1</td>
</tr>
<tr>
<td>Greece</td>
<td>674.3</td>
<td>178.3</td>
<td>62.5</td>
<td>50.4</td>
<td>25.6</td>
<td>50.2</td>
<td>75.8</td>
<td>36.4</td>
<td>16.7</td>
<td>51.7</td>
</tr>
<tr>
<td>Norway</td>
<td>548.0</td>
<td>197.1</td>
<td>68.7</td>
<td>64.3</td>
<td>34.6</td>
<td>14.1</td>
<td>48.7</td>
<td>52.5</td>
<td>5.7</td>
<td>99.6</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>903.0</td>
<td>213.7</td>
<td>128.8</td>
<td>94.0</td>
<td>28.8</td>
<td>59.2</td>
<td>88.0</td>
<td>78.3</td>
<td>41.5</td>
<td>91.7</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>606.2</td>
<td>134.7</td>
<td>79.9</td>
<td>50.8</td>
<td>29.4</td>
<td>21.7</td>
<td>51.1</td>
<td>51.2</td>
<td>28.8</td>
<td>107.2</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown.
### Table A.4.6 Prevalence counts, by established therapy (patients alive on December 31)

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL N</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital</td>
<td>Centre</td>
<td>Home</td>
<td>HD type unknown</td>
<td>Haemofiltration (HF)</td>
<td>Haemodiafiltration (HDF)</td>
</tr>
<tr>
<td>Austria</td>
<td>5320</td>
<td>2289</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>337</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>4294</td>
<td>1757</td>
<td>7</td>
<td>263</td>
<td>2</td>
<td>203</td>
</tr>
<tr>
<td>Greece</td>
<td>7428</td>
<td>5482</td>
<td>1</td>
<td>0</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Norway</td>
<td>2307</td>
<td>434</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>5661</td>
<td>3124</td>
<td>5</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>9141</td>
<td>3162</td>
<td>82</td>
<td>0</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

*" is unavailable
### Section A  Countries collecting individual patient data (included in ERA-EDTA registry database)

#### Table A.4.7 Prevalence per million population, by established therapy (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th></th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Hospital/Centre</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>663.9</td>
<td>285.6</td>
<td>0.6</td>
<td>0.2</td>
<td>0.2</td>
<td>42.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>328.8</td>
<td>3.4</td>
<td>25.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>29.2</td>
<td>18.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>305.7</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.0</td>
<td>313.1</td>
<td>0</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>726.3</td>
<td>297.2</td>
<td>1.2</td>
<td>0.3</td>
<td>34.3</td>
<td>377.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16.1</td>
<td>18.6</td>
<td>10.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35.7</td>
<td>4.6</td>
<td>121.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>186.7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>706.3</td>
<td>521.3</td>
<td>0.1</td>
<td>0</td>
<td>1.2</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>523.2</td>
<td>1.2</td>
<td>59.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
<td>61.4</td>
<td>59.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>61.9</td>
<td>0</td>
<td>121.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>520.6</td>
<td>97.9</td>
<td>0.2</td>
<td>0</td>
<td>0</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>98.6</td>
<td>7.4</td>
<td>15.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>22.6</td>
<td>197.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>399.2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>927.3</td>
<td>511.7</td>
<td>0.8</td>
<td>0</td>
<td>1.2</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>512.5</td>
<td>14.3</td>
<td>13.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>27.8</td>
<td>13.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>373.1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>386.9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>582.0</td>
<td>201.3</td>
<td>5.2</td>
<td>0</td>
<td>0</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>206.5</td>
<td>22.3</td>
<td>64.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>86.8</td>
<td>45.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>242.8</td>
<td>0.2</td>
<td>288.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.3</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

*" is unavailable
### Table A.4.8 Prevalence per million population, by established therapy (patients alive on December 31, adjusted for age and gender)

<table>
<thead>
<tr>
<th></th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Hospital Centre</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Home</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>HD type unknown</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Haemofiltration (HF)</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Haemodiafiltration (HDF)</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Total HD HF/HDF</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>APD</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>CAPD</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>PD type unknown</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Total PD</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Living</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Cadaveric</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Tx type unknown</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
<tr>
<td>Total Tx</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
<td>PMP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>673.3</td>
<td>290.4</td>
<td>0.6</td>
<td>0.2</td>
<td>0.3</td>
<td>43.0</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>709.0</td>
<td>290.3</td>
<td>1.2</td>
<td>44.9</td>
<td>0.3</td>
<td>32.3</td>
</tr>
<tr>
<td>Greece</td>
<td>674.3</td>
<td>496.0</td>
<td>0.1</td>
<td>0</td>
<td>1.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Norway</td>
<td>548.0</td>
<td>103.5</td>
<td>0.2</td>
<td>0</td>
<td>0</td>
<td>0.4</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>903.0</td>
<td>494.4</td>
<td>0.8</td>
<td>0</td>
<td>0</td>
<td>0.4</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>606.2</td>
<td>222.3</td>
<td>5.2</td>
<td>0</td>
<td>0</td>
<td>0.4</td>
</tr>
</tbody>
</table>

*" is unavailable
Table A.4.9  Percentage of established therapy (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Unknown</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital Centre</td>
<td>Home</td>
<td>HD type unknown</td>
<td>Haemofiltration (HF)</td>
<td>Haemodiafiltration (HDF)</td>
<td>Total HD/HF/HDF</td>
</tr>
<tr>
<td>Austria</td>
<td>100</td>
<td>43</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>100</td>
<td>41</td>
<td>0</td>
<td>6</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Greece</td>
<td>100</td>
<td>74</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>100</td>
<td>19</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>100</td>
<td>55</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>55</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>100</td>
<td>35</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>35</td>
</tr>
</tbody>
</table>

Categories may not add up to total or to 100% because of missing values
"." is unavailable
### Table A.4.10 Percentage of established therapy by age group, gender and diabetic status (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>ALL</th>
<th>0-19</th>
<th>20-44</th>
<th>45-64</th>
<th>65-74</th>
<th>75+</th>
<th>Male</th>
<th>Female</th>
<th>Diabetes Mellitus</th>
<th>Non DM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HD</td>
<td>PD</td>
<td>TX</td>
<td>Oth</td>
<td>HD</td>
<td>PD</td>
<td>TX</td>
<td>Oth</td>
<td>HD</td>
<td>PD</td>
</tr>
<tr>
<td>Austria</td>
<td>43</td>
<td>4</td>
<td>46</td>
<td>6</td>
<td>10</td>
<td>9</td>
<td>80</td>
<td>1</td>
<td>28</td>
<td>4</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>47</td>
<td>5</td>
<td>43</td>
<td>5</td>
<td>13</td>
<td>11</td>
<td>76</td>
<td>0</td>
<td>24</td>
<td>6</td>
</tr>
<tr>
<td>Greece</td>
<td>75</td>
<td>11</td>
<td>19</td>
<td>5</td>
<td>24</td>
<td>20</td>
<td>56</td>
<td>0</td>
<td>54</td>
<td>5</td>
</tr>
<tr>
<td>Norway</td>
<td>19</td>
<td>4</td>
<td>77</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td>90</td>
<td>0</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>55</td>
<td>3</td>
<td>42</td>
<td>0</td>
<td>28</td>
<td>7</td>
<td>66</td>
<td>0</td>
<td>34</td>
<td>3</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>35</td>
<td>15</td>
<td>50</td>
<td>0</td>
<td>15</td>
<td>20</td>
<td>65</td>
<td>0</td>
<td>20</td>
<td>17</td>
</tr>
</tbody>
</table>

Categories may not add up to total or to 100% because of missing values.
### Table A.4.11  Patients living on a functioning graft (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th></th>
<th>ALL</th>
<th>Living</th>
<th>Cadaveric</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Related</td>
<td>Unrelated</td>
<td>Type Unknown</td>
<td>All Living</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Austria</td>
<td>2450</td>
<td>100</td>
<td>131</td>
<td>5</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>1851</td>
<td>100</td>
<td>21</td>
<td>1</td>
</tr>
<tr>
<td>Greece</td>
<td>1279</td>
<td>100</td>
<td>628</td>
<td>49</td>
</tr>
<tr>
<td>Norway</td>
<td>1769</td>
<td>100</td>
<td>768</td>
<td>43</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>2362</td>
<td>100</td>
<td>84</td>
<td>4</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>4528</td>
<td>100</td>
<td>712</td>
<td>16</td>
</tr>
</tbody>
</table>

*Categories may not add up to total or to 100% because of missing values

"." is unavailable
# Section B

## AFFILIATED REGISTRY INFORMATION

### Table B.1.1 General population of the country/region by age group and gender, and percent coverage of the general population

<table>
<thead>
<tr>
<th>Country</th>
<th>General population in Thousands</th>
<th>% coverage of general population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group</td>
<td>All</td>
<td>0-19</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td><strong>General population</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Country</strong></td>
<td><strong>General population</strong></td>
<td><strong>% coverage</strong></td>
</tr>
<tr>
<td><strong>All</strong></td>
<td><strong>All</strong></td>
<td><strong>All</strong></td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basque country</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All</strong></td>
<td>2104.8</td>
<td>40.3</td>
</tr>
<tr>
<td><strong>Estonia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All</strong></td>
<td>1400</td>
<td>20.5</td>
</tr>
<tr>
<td><strong>Germany</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td>1595.2</td>
<td>105.2</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Poland</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td>3866.6</td>
<td>926.6</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Serbia and Montenegro</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td>4032.9</td>
<td>403.2</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Valencia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td>5462.0</td>
<td>206.2</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Mid year population as provided by the national statistics agency or Eurostat
2. % of the general population covered by the renal centres collaborating with the registry

---

**Notes:**
- Countries collecting individual patient data, information via centre questionnaires or health authorities.
- Not included in ERA-EDTA registry database.
Section B  Countries collecting individual patient data, information via centre questionnaires or health authorities
(not included in ERA-EDTA registry database)  May 20, 2003

Table B.1.2  Renal centres\(^1\): total number of centres and number collaborating

<table>
<thead>
<tr>
<th>Country</th>
<th>Total number of renal centres</th>
<th>Number of renal centres collaborating with the registry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basque country</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>1021</td>
<td>947</td>
</tr>
<tr>
<td>Poland</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>54</td>
<td>49</td>
</tr>
<tr>
<td>Valencia</td>
<td>40</td>
<td>40</td>
</tr>
</tbody>
</table>

\(^1\) The number of renal centres is based on having a separate centre code
## B.2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 1

Table B.2.1 Incident counts and incident rates per million population (at day 1, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>N</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
<th>Pmp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>129</td>
<td></td>
<td></td>
<td></td>
<td>124.4</td>
</tr>
<tr>
<td>Women</td>
<td>81</td>
<td></td>
<td></td>
<td></td>
<td>75.3</td>
</tr>
<tr>
<td>All</td>
<td>210</td>
<td></td>
<td></td>
<td></td>
<td>99.4</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>34.5</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>6892</td>
<td></td>
<td></td>
<td></td>
<td>172</td>
</tr>
<tr>
<td>Women</td>
<td>5227</td>
<td></td>
<td></td>
<td></td>
<td>124</td>
</tr>
<tr>
<td>All</td>
<td>12119</td>
<td></td>
<td></td>
<td></td>
<td>148</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>2010</td>
<td></td>
<td></td>
<td></td>
<td>52</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>1042</td>
<td></td>
<td></td>
<td></td>
<td>98.2</td>
</tr>
<tr>
<td>Valencia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>374</td>
<td></td>
<td></td>
<td></td>
<td>189.7</td>
</tr>
<tr>
<td>Women</td>
<td>243</td>
<td></td>
<td></td>
<td></td>
<td>118.4</td>
</tr>
<tr>
<td>All</td>
<td>617</td>
<td></td>
<td></td>
<td></td>
<td>153.3</td>
</tr>
</tbody>
</table>
### Table B.2.2  Gender, mean and median age of incident patients (at day 1)

<table>
<thead>
<tr>
<th>Country</th>
<th>Gender</th>
<th>Mean age (SD)</th>
<th>Median age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>Years</td>
<td>Years</td>
</tr>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>61.4</td>
<td>57.2 (16)</td>
<td>61</td>
</tr>
<tr>
<td>Women</td>
<td>38.6</td>
<td>59.2 (18)</td>
<td>65</td>
</tr>
<tr>
<td>All</td>
<td>57.9 (16.7)</td>
<td></td>
<td>62.5</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>59.9</td>
<td>60.3 (15.1)</td>
<td>63</td>
</tr>
<tr>
<td>Women</td>
<td>43.1</td>
<td>63.8 (15.5)</td>
<td>68</td>
</tr>
<tr>
<td>All</td>
<td>61.8 (15.4)</td>
<td></td>
<td>65</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>48.1 (12.8)</td>
<td></td>
<td>57</td>
</tr>
<tr>
<td>Valencia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>49.0</td>
<td>59.9</td>
<td>64</td>
</tr>
<tr>
<td>Women</td>
<td>51.0</td>
<td>60.8</td>
<td>64</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>60.2</td>
<td>64</td>
</tr>
</tbody>
</table>
## Table B.2.3  Incident rates per million population (at day 1, adjusted for age and gender)*

<table>
<thead>
<tr>
<th>Country</th>
<th>Pmp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basque country</td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td>124.2</td>
</tr>
<tr>
<td>Women¹</td>
<td>69.3</td>
</tr>
<tr>
<td>All²</td>
<td>96.7</td>
</tr>
<tr>
<td>All³</td>
<td>187.3</td>
</tr>
<tr>
<td>Estonia</td>
<td>179</td>
</tr>
<tr>
<td>All³</td>
<td>106</td>
</tr>
<tr>
<td>Germany</td>
<td>142</td>
</tr>
<tr>
<td>All³</td>
<td>151.4</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>187.3</td>
</tr>
<tr>
<td>All³</td>
<td>117.0</td>
</tr>
<tr>
<td>All³</td>
<td>151.4</td>
</tr>
</tbody>
</table>

* adjustment to European population of 1995 (see Methods section); ¹adjusted for age; ²adjusted for age and gender
Table B.2.4 Incident rates per million population and percentage, by cause of renal failure (at day 1, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pmp</td>
<td>%</td>
<td>Pmp</td>
<td>%</td>
<td>Pmp</td>
<td>%</td>
<td>Pmp</td>
<td>%</td>
<td>Pmp</td>
<td>%</td>
</tr>
<tr>
<td>Basque country</td>
<td>99.4</td>
<td>100</td>
<td>18.5</td>
<td>18.6</td>
<td>11.8</td>
<td>11.9</td>
<td>8.5</td>
<td>8.6</td>
<td>4.3</td>
<td>9</td>
</tr>
<tr>
<td>Estonia</td>
<td>34.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>148</td>
<td>100</td>
<td>25</td>
<td>17.1</td>
<td>12</td>
<td>8.3</td>
<td>5</td>
<td>3.4</td>
<td>9</td>
<td>6.3</td>
</tr>
<tr>
<td>Poland</td>
<td>52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>98.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>153.3</td>
<td>100</td>
<td>24.1</td>
<td>15.7</td>
<td>18.6</td>
<td>12.2</td>
<td>10.7</td>
<td>7</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown.

1 Grouping renal disease see Methods section
### B.3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 90

Table B.3.1  Incident counts and incident rates per million population (at day 90, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>N</th>
<th>Pmp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>358</td>
<td>181.6</td>
</tr>
<tr>
<td>Men</td>
<td>221</td>
<td>107.6</td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>579</td>
<td>143.9</td>
</tr>
</tbody>
</table>
### Section B  Countries collecting individual patient data, information via centre questionnaires or health authorities  
(not included in ERA-EDTA registry database)  

**Table B.3.2**  Gender, mean and median age of incident patients (at day 90)

<table>
<thead>
<tr>
<th>Country</th>
<th>Gender</th>
<th>Mean age (SD)</th>
<th>Median age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>Years</td>
<td>Years</td>
</tr>
<tr>
<td>Basque country</td>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>Men</td>
<td>61.8</td>
<td>59.6</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>38.2</td>
<td>60.0</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>100</td>
<td>64</td>
</tr>
<tr>
<td>Country</td>
<td>Pmp</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td>181.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td>107.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All²</td>
<td>143.6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* adjustment to European population of 1995 (see Methods section); ¹ adjusted for age; ² adjusted for age and gender
### Table B.3.4 Incident rates per million population and percentage, by cause of renal failure\(^1\) (at day 90, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pmp</td>
<td>%</td>
<td>Pmp%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>143.9</td>
<td>23.1</td>
<td>16.1</td>
<td>12.6</td>
<td>7.3</td>
<td>19.1</td>
<td>13.3</td>
<td>23.9</td>
<td>16.6</td>
<td>3.3</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown.

\(^1\) Grouping renal disease see Methods section.
### Section B  Countries collecting individual patient data, information via centre questionnaires or health authorities

*(not included in ERA-EDTA registry database)*

#### May 20, 2003

Table B.3.5  Incident counts, by established therapy (at day 90)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Basque country</td>
<td>137</td>
<td>137</td>
<td>2</td>
<td>56</td>
<td>58</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>579</td>
<td>501</td>
<td>1</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>502</td>
<td></td>
<td>70</td>
<td>70</td>
<td>7</td>
</tr>
</tbody>
</table>

For Basque country treatment refers to the last treatment of incident patients in every year; For Germany treatment modalities refer to day 1.
Table B.3.6  Incident rates per million population, by established therapy (at day 90, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital/centre</td>
<td>Home</td>
<td>HD, type unknown</td>
<td>HF</td>
<td>HDF</td>
</tr>
<tr>
<td></td>
<td>Pmp</td>
<td>Pmp</td>
<td>Pmp</td>
<td>Pmp</td>
<td>Pmp</td>
</tr>
<tr>
<td>Basque country</td>
<td>64.9 Pmp</td>
<td>64.9 Pmp</td>
<td>64.9 Pmp</td>
<td>0.9 Pmp</td>
<td>26.5 Pmp</td>
</tr>
<tr>
<td>Estonia</td>
<td>148 Pmp</td>
<td>137 Pmp</td>
<td>9 Pmp</td>
<td>0 Pmp</td>
<td>0 Pmp</td>
</tr>
<tr>
<td>Germany</td>
<td>143.9 Pmp</td>
<td>124.5 Pmp</td>
<td>0.2 Pmp</td>
<td>0 Pmp</td>
<td>- Pmp</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>143.9 Pmp</td>
<td>124.5 Pmp</td>
<td>0.2 Pmp</td>
<td>0 Pmp</td>
<td>- Pmp</td>
</tr>
</tbody>
</table>

For Basque country treatment refers to the last treatment of incident patients in every year; For Germany treatment modalities refer to day 1
### Table B.3.7 Percentage of established therapy (at day 90, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>Hospital/centre</td>
<td>Home</td>
<td>HD, type unknown</td>
<td>HD</td>
</tr>
<tr>
<td>Basque country</td>
<td>100</td>
<td>65.2</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Estonia</td>
<td>100</td>
<td>93</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Germany</td>
<td>100</td>
<td>86.5</td>
<td>0.2</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>100</td>
<td>86.5</td>
<td>0.2</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

For Basque country treatment refers to the last treatment of incident patients in every year; For Germany treatment modalities refer to day 1
### B.4 PREVALENT PATIENTS ON RRT ON DECEMBER 31, 1998 (residents only)

Table B.4.1 Prevalent counts and per million population (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>N</th>
<th>Pmp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>853</td>
<td>828.4</td>
</tr>
<tr>
<td>Women</td>
<td>574</td>
<td>533.9</td>
</tr>
<tr>
<td>All</td>
<td>1427</td>
<td>675.6</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td>162</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>35304</td>
<td>883</td>
</tr>
<tr>
<td>Women</td>
<td>27353</td>
<td>651</td>
</tr>
<tr>
<td>All</td>
<td>62657 (47973)</td>
<td>764 (585)</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>4287</td>
<td>110.9</td>
</tr>
<tr>
<td>Women</td>
<td>5457</td>
<td>141.1</td>
</tr>
<tr>
<td>All</td>
<td>9744</td>
<td>252</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>3785</td>
<td>357.1</td>
</tr>
<tr>
<td>Valencia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>2156</td>
<td>1094</td>
</tr>
<tr>
<td>Women</td>
<td>1500</td>
<td>730.8</td>
</tr>
<tr>
<td>All</td>
<td>3656</td>
<td>908.7</td>
</tr>
</tbody>
</table>
### Table B.4.2  Gender, mean and median age of prevalent patients (alive on December 31)

<table>
<thead>
<tr>
<th>Country</th>
<th>Gender</th>
<th>Mean age (SD)</th>
<th>Median age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>Years</td>
<td></td>
</tr>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>59.8</td>
<td>53.9 (15.1)</td>
<td>55</td>
</tr>
<tr>
<td>Women</td>
<td>40.2</td>
<td>53.5 (16)</td>
<td>56</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>53.8 (15.5)</td>
<td>55</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>56.3</td>
<td>56.8 (15.5)</td>
<td>59</td>
</tr>
<tr>
<td>Women</td>
<td>43.7</td>
<td>60 (16.1)</td>
<td>63</td>
</tr>
<tr>
<td>All</td>
<td></td>
<td>58.2 (15.8)</td>
<td>61</td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td>48.0 (13.3)</td>
<td>54</td>
</tr>
<tr>
<td>Valencia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>58.9</td>
<td>56.0</td>
<td>58</td>
</tr>
<tr>
<td>Women</td>
<td>41.0</td>
<td>57.5</td>
<td>60</td>
</tr>
<tr>
<td>All</td>
<td>100</td>
<td>56.6</td>
<td>59</td>
</tr>
</tbody>
</table>
### Table B.4.3  Prevalence per million population (patients alive on December 31, adjusted for age and gender)*

<table>
<thead>
<tr>
<th>Country</th>
<th>Pmp</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basque country</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td>837.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td>539.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All¹</td>
<td>688.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td>880</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All¹</td>
<td>573</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td>880</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td>573</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All¹</td>
<td>722</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men¹</td>
<td>1091.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women¹</td>
<td>729.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All¹</td>
<td>906.9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* adjustment to European population of 1995 (see Methods section); ¹adjusted for age; ²adjusted for age and gender
### Table B.4.4 Prevalence per million population and percentage, by cause of renal failure

**Table B.4.4 Prevalence per million population and percentage, by cause of renal failure (patients alive on December 31, unadjusted)**

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>GN</th>
<th>PN</th>
<th>PKD</th>
<th>DM</th>
<th>HT</th>
<th>RVD</th>
<th>Misc</th>
<th>Unkn</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pmp</td>
<td>% Pmp</td>
<td>Pmp</td>
<td>% Pmp</td>
<td>Pmp</td>
<td>% Pmp</td>
<td>Pmp</td>
<td>% Pmp</td>
<td>Pmp</td>
<td>% Pmp</td>
</tr>
<tr>
<td><strong>Basque country</strong></td>
<td>676</td>
<td>100</td>
<td>200</td>
<td>29.6</td>
<td>91</td>
<td>13.3</td>
<td>73</td>
<td>10.8</td>
<td>22</td>
<td>3.3</td>
</tr>
<tr>
<td>Estonia</td>
<td>162</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>764</td>
<td>191</td>
<td>25</td>
<td>7.1</td>
<td>93</td>
<td>12.1</td>
<td>46</td>
<td>6</td>
<td>42</td>
<td>5.6</td>
</tr>
<tr>
<td>Poland²</td>
<td>178</td>
<td>100</td>
<td>67</td>
<td>37.4</td>
<td>32</td>
<td>17.9</td>
<td>15</td>
<td>8.6</td>
<td>21</td>
<td>11.6</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>357.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>908.7</td>
<td>100</td>
<td>181.7</td>
<td>20</td>
<td>141.9</td>
<td>15.6</td>
<td>83.7</td>
<td>9.2</td>
<td>65.1</td>
<td>7.2</td>
</tr>
</tbody>
</table>

Abbreviations used: GN: Glomerulonephritis/sclerosis; PN: Pyelonephritis; PKD: Polycystic kidneys, adult type; DM: Diabetes mellitus; HT: Hypertension; RVD: Renal vascular disease; Misc: Miscellaneous; Unkn: Unknown.

1 Grouping renal disease see Methods section; ² Data refer to dialysis population only.
### Table B.4.5 Prevalence counts, by established therapy (patients alive on December 31)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital/ Centre</td>
<td>Home</td>
<td>HD, type unknown</td>
<td>HF</td>
<td>HDF</td>
</tr>
<tr>
<td>Basque country</td>
<td>439</td>
<td>1</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Estonia</td>
<td>62657</td>
<td>44393</td>
<td>638</td>
<td>5722</td>
<td>735</td>
</tr>
<tr>
<td>Germany</td>
<td>9744</td>
<td>6150</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Poland</td>
<td>3785</td>
<td>3076</td>
<td>60</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>3656</td>
<td>2258</td>
<td>4</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>
# Section B  
Countries collecting individual patient data, information via centre questionnaires or health authorities  
*not included in ERA-EDTA registry database*  
May 20, 2003

Table B.4.6  
Prevalence per million population, by established therapy (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Hospital/centre</td>
<td>Home</td>
<td>HD, type unknown</td>
<td>HD</td>
</tr>
<tr>
<td>Basque country</td>
<td>Pmp</td>
<td>Pmp</td>
<td>Pmp</td>
<td>Pmp</td>
<td>Pmp</td>
</tr>
<tr>
<td>Estonia</td>
<td>162</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>549</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>252</td>
<td>159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>357.1</td>
<td>290.2</td>
<td>5.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valencia</td>
<td>908.7</td>
<td>561.2</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | 51 |
### Table B.4.7 Percentage of established therapy (patients alive on December 31, unadjusted)

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Haemodialysis</th>
<th>Peritoneal dialysis</th>
<th>Transplant</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Hospital/centre</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Home</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>HD, type unknown</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>HF</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>HDF</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Total HD/HF/HDF</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>APD</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>CAPD</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>PD, type unknown</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Total PD</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Living</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Cadaveric</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Tx, type unknown</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Total Tx</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Basque country</td>
<td>30.7</td>
<td>0.1</td>
<td>30.8</td>
<td>0.2</td>
<td>10.7</td>
</tr>
<tr>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td>75.8</td>
<td>4.9</td>
<td>24.7</td>
</tr>
<tr>
<td>Poland</td>
<td>100</td>
<td>63.1</td>
<td>63.1</td>
<td>0.8</td>
<td>6.6</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>100</td>
<td>81</td>
<td>1.6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Valencia</td>
<td>100</td>
<td>61.8</td>
<td>0.1</td>
<td>61.9</td>
<td>4.8</td>
</tr>
</tbody>
</table>
### Table B.4.8 Renal transplants, number and percentage by donor type

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL</th>
<th>Living</th>
<th>Cadaveric</th>
<th>Donor type unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Related</td>
<td>Living, type unknown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Basque country</td>
<td>142</td>
<td>100</td>
<td>142</td>
<td>100</td>
</tr>
<tr>
<td>Estonia</td>
<td>2340</td>
<td></td>
<td>343</td>
<td>14,7</td>
</tr>
<tr>
<td>Germany</td>
<td>407</td>
<td>100</td>
<td>265</td>
<td>65</td>
</tr>
<tr>
<td>Poland</td>
<td>224</td>
<td>100</td>
<td>224</td>
<td>100</td>
</tr>
<tr>
<td>Serbia and Montenegro</td>
<td>224</td>
<td>100</td>
<td>224</td>
<td>100</td>
</tr>
</tbody>
</table>
**Section C  Methods  May 20, 2003**

**General population base, patients and reference population for 1998**

Methods used in section A: countries collecting individual patient data (included in ERA-EDTA registry database)

<table>
<thead>
<tr>
<th></th>
<th>General population Base</th>
<th>Patients</th>
<th>Reference population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A.1 AFFILIATED REGISTRY INFORMATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table A.1.1</td>
<td>General population of the country/region by age group and gender, and percent coverage in 1998</td>
<td>1998</td>
<td></td>
</tr>
<tr>
<td>Table A.1.2</td>
<td>Renal centres: total number of centres and number collaborating</td>
<td>1998</td>
<td></td>
</tr>
<tr>
<td><strong>A.2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 1</strong></td>
<td></td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table A.2.1</td>
<td>Incident counts and percentage, by age group and gender (at day 1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table A.2.2</td>
<td>Gender, mean and median age of incident patients (at day 1)</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table A.2.3</td>
<td>Incident rates per million population, by age group and gender (at day 1, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
</tr>
<tr>
<td>Table A.2.4</td>
<td>Incident rates per million population and percentage, by cause of renal failure (at day 1, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
</tr>
<tr>
<td>Table A.2.5</td>
<td>Incident rates per million population, by cause of renal failure (at day 1, adjusted for age and gender)</td>
<td>1998</td>
<td>EUR 1995</td>
</tr>
<tr>
<td><strong>A.3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 90</strong></td>
<td></td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table A.3.1</td>
<td>Incident counts and percentage, by age group and gender (at day 90)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table A.3.2</td>
<td>Gender, mean and median age of incident patients (at day 90)</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table A.3.3</td>
<td>Incident rates per million population, by age group and gender (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
</tr>
<tr>
<td>Table A.3.4</td>
<td>Incident rates per million population and percentage, by cause of renal failure (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
</tr>
<tr>
<td>Table A.3.5</td>
<td>Incident rates per million population, by cause of renal failure (at day 90, adjusted for age and gender)</td>
<td>1998</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table A.3.6</td>
<td>Incident counts, by established therapy (at day 90)</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table A.3.7</td>
<td>Incident rates per million population, by established therapy (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
</tr>
<tr>
<td>Table A.3.8</td>
<td>Incident rates per million population, by established therapy (at day 90, adjusted for age and gender)</td>
<td>1998</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table A.3.9</td>
<td>Percentage of established therapy (at day 90, unadjusted)</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table A.3.10</td>
<td>Percentage of established therapy by age group, gender and diabetic status (at day 90, unadjusted)</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td><strong>A.4 PREVALENT PATIENTS ON RRT IN 1998 (residents only)</strong></td>
<td></td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.1</td>
<td>Prevalence counts and percentage, by age group and gender (patients alive on December 31)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.2</td>
<td>Mean and median age of prevalent patients (alive on December 31)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.3</td>
<td>Prevalence per million population, by age group and gender (patients alive on December 31, unadjusted)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.4</td>
<td>Prevalence per million population and percentage, by cause of renal failure (patients alive on December 31, unadjusted)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.5</td>
<td>Prevalence per million population, by cause of renal failure (patients alive on December 31, adjusted for age and gender)</td>
<td>31-12-98</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table A.4.6</td>
<td>Prevalence counts, by established therapy (patients alive on December 31)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.7</td>
<td>Prevalence per million population, by established therapy (patients alive on December 31, unadjusted)</td>
<td>31-12-98</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table A.4.8</td>
<td>Prevalence per million population, by established therapy (patients alive on December 31, adjusted for age and gender)</td>
<td>31-12-98</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table A.4.9</td>
<td>Percentage of established therapy (patients alive on December 31, unadjusted)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.10</td>
<td>Percentage of established therapy by age group, gender and diabetic status (patients alive on December 31, unadjusted)</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table A.4.11</td>
<td>Renal transplants, number and percentage by donor type</td>
<td>010198-311298</td>
<td></td>
</tr>
</tbody>
</table>
Methods used in section B: countries collecting individual patient data, information via centre questionnaires or health authorities (not included in ERA-EDTA registry database)

<table>
<thead>
<tr>
<th>B.1 AFFILIATED REGISTRY INFORMATION</th>
<th>General population Base</th>
<th>Patients</th>
<th>Reference population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table B.1.1 General population of the country/region by age group and gender, and percent coverage of the general population</td>
<td>1998</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table B.1.2 Renal centres: total number of centres and number collaborating</td>
<td>1998</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B.2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 1</th>
<th>General population Base</th>
<th>Patients</th>
<th>Reference population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table B.2.1 Incident counts and incident rates per million population (at day 1, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.2.2 Gender, mean and median age of incident patients (at day 1)</td>
<td></td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.2.3 Incident rates per million population (at day 1, adjusted for age and gender)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table B.2.4 Incident rates per million population and percentage, by cause of renal failure (at day 1, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B.3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 1998 (residents only) AT DAY 90</th>
<th>General population Base</th>
<th>Patients</th>
<th>Reference population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table B.3.1 Incident counts and incident rates per million population (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.3.2 Gender, mean and median age of incident patients (at day 90)</td>
<td></td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.3.3 Incident rates per million population (at day 90, adjusted for age and gender)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table B.3.4 Incident rates per million population and percentage, by cause of renal failure (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.3.5 Incident counts, by established therapy (at day 90)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.3.6 Incident rates per million population, by established therapy (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
<tr>
<td>Table B.3.7 Percentage of established therapy (at day 90, unadjusted)</td>
<td>1998</td>
<td>Cohort 1998</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B.4 PREVALENT PATIENTS ON RRT IN 1998 (residents only)</th>
<th>General population Base</th>
<th>Patients</th>
<th>Reference population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table B.4.1 Prevalent counts and per million population (patients alive on December 31, unadjusted)</td>
<td>1998</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table B.4.2 Gender, mean and median age of prevalent patients (alive on December 31)</td>
<td></td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table B.4.3 Prevalence per million population (patients alive on December 31, adjusted for age and gender)</td>
<td>1998</td>
<td>31-12-98</td>
<td>EUR 1995</td>
</tr>
<tr>
<td>Table B.4.4 Prevalence per million population and percentage, by cause of renal failure (patients alive on December 31, unadjusted)</td>
<td>1998</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table B.4.5 Prevalence counts, by established therapy (patients alive on December 31)</td>
<td>31-12-98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table B.4.6 Prevalence per million population, by established therapy (patients alive on December 31, unadjusted)</td>
<td>1998</td>
<td>31-12-98</td>
<td></td>
</tr>
<tr>
<td>Table B.4.7 Percentage of established therapy (patients alive on December 31, unadjusted)</td>
<td>31-12-98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table B.4.8 Renal transplants, number and percentage by donor type</td>
<td></td>
<td></td>
<td>010198-311298</td>
</tr>
</tbody>
</table>
These analyses are based on databases reported on:

<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>02OCT2001</td>
</tr>
<tr>
<td>Belgium, Dutch-speaking</td>
<td>13DEC2001</td>
</tr>
<tr>
<td>Greece</td>
<td>16JAN2002</td>
</tr>
<tr>
<td>Norway</td>
<td>22OCT2001</td>
</tr>
<tr>
<td>Spain, Catalonia</td>
<td>19MAR2002</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>01NOV2001</td>
</tr>
</tbody>
</table>
## Grouping of renal diseases

<table>
<thead>
<tr>
<th>Primary Renal Disease (PRD)</th>
<th>1994 code</th>
<th>1995 code</th>
<th>PRD Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glomerulonephritis; histologically NOT examined</td>
<td>10</td>
<td>10</td>
<td>I</td>
</tr>
<tr>
<td>Focal segmental glomerulosclerosis with nephrotic syndrome in children</td>
<td>11</td>
<td>11</td>
<td>I</td>
</tr>
<tr>
<td>IgA nephropathy (proven by immunofluorescence, not code 76 and not 85)</td>
<td>12</td>
<td>12</td>
<td>I</td>
</tr>
<tr>
<td>Dense deposit disease; membrano-proliferative GN; type II (proven by immunofluorescence and/or electron microscopy)</td>
<td>13</td>
<td>13</td>
<td>I</td>
</tr>
<tr>
<td>Membranous nephropathy</td>
<td>14</td>
<td>14</td>
<td>I</td>
</tr>
<tr>
<td>Membrano-proliferative GN; type I (proven by immunofluorescence and/or electron microscopy - not code 84 or 89)</td>
<td>15</td>
<td>15</td>
<td>I</td>
</tr>
<tr>
<td>Crescentic (extracapillary) glomerulonephritis (type I, II, III)</td>
<td>16</td>
<td>16</td>
<td>I</td>
</tr>
<tr>
<td>Focal segmental glomerulosclerosis with nephrotic syndrome in adults</td>
<td>17</td>
<td>17</td>
<td>I</td>
</tr>
<tr>
<td>Glomerulonephritis; histologically examined, not given above</td>
<td>19</td>
<td>19</td>
<td>I</td>
</tr>
<tr>
<td>Pyelonephritis - cause not specified</td>
<td>20</td>
<td>20</td>
<td>II</td>
</tr>
<tr>
<td>Pyelonephritis associated with neurogenic bladder</td>
<td>21</td>
<td>21</td>
<td>II</td>
</tr>
<tr>
<td>Pyelonephritis due to congenital obstructive uropathy with/without vesico-ureteric reflux</td>
<td>22</td>
<td>22</td>
<td>II</td>
</tr>
<tr>
<td>Pyelonephritis due to acquired obstructive uropathy</td>
<td>23</td>
<td>23</td>
<td>II</td>
</tr>
<tr>
<td>Pyelonephritis due to vesico-ureteric reflux without obstruction</td>
<td>24</td>
<td>24</td>
<td>II</td>
</tr>
<tr>
<td>Pyelonephritis due to urolithiasis</td>
<td>25</td>
<td>25</td>
<td>II</td>
</tr>
<tr>
<td>Pyelonephritis due to other cause</td>
<td>29</td>
<td>29</td>
<td>II</td>
</tr>
<tr>
<td>Interstitial nephritis (not pyelonephritis) due to other cause, or unspecified (not mentioned above)</td>
<td>30</td>
<td>30</td>
<td>VII</td>
</tr>
<tr>
<td>Nephropathy (interstitial) due to analgesic drugs</td>
<td>31</td>
<td>31</td>
<td>VII</td>
</tr>
<tr>
<td>Nephropathy (interstitial) due to cis-platinum</td>
<td>32</td>
<td>32</td>
<td>VII</td>
</tr>
<tr>
<td>Nephropathy (interstitial) due to cyclosporin A</td>
<td>33</td>
<td>33</td>
<td>VII</td>
</tr>
<tr>
<td>Lead induced nephropathy (interstitial)</td>
<td>34</td>
<td>34</td>
<td>VII</td>
</tr>
<tr>
<td>Drug induced nephropathy (interstitial) not mentioned above</td>
<td>39</td>
<td>39</td>
<td>VII</td>
</tr>
<tr>
<td>Cystic kidney disease - type unspecified</td>
<td>40</td>
<td>40</td>
<td>VII</td>
</tr>
<tr>
<td>Polycystic kidneys; adult type (dominant)</td>
<td>41</td>
<td>41</td>
<td>III</td>
</tr>
<tr>
<td>Polycystic kidneys; infantile (recessive)</td>
<td>42</td>
<td>42</td>
<td>VII</td>
</tr>
<tr>
<td>Medullary cystic disease; including nephronopthisis</td>
<td>43</td>
<td>43</td>
<td>VII</td>
</tr>
<tr>
<td>Cystic kidney disease - other specified type</td>
<td>49</td>
<td>49</td>
<td>VII</td>
</tr>
<tr>
<td>Hereditary/Familial nephropathy - type unspecified</td>
<td>50</td>
<td>50</td>
<td>VII</td>
</tr>
<tr>
<td>Hereditary nephritis with nerve deafness (Alport's Syndrome)</td>
<td>51</td>
<td>51</td>
<td>VII</td>
</tr>
<tr>
<td>Cystinosis</td>
<td>52</td>
<td>52</td>
<td>VII</td>
</tr>
<tr>
<td>Primary oxalosis</td>
<td>53</td>
<td>53</td>
<td>VII</td>
</tr>
<tr>
<td>Fabry's disease</td>
<td>54</td>
<td>54</td>
<td>VII</td>
</tr>
<tr>
<td>Section C  Methods</td>
<td>May 20, 2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hereditary nephropathy - other specified type</td>
<td>59</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Renal hypoplasia (congenital) - type unspecified</td>
<td>60</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Oligomeganephronic hypoplasia</td>
<td>61</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Congenital renal dysplasia with or without urinary tract malformation</td>
<td>63</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Syndrome of agenesis of abdominal muscles (Prune Belly)</td>
<td>66</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Renal vascular disease - type unspecified</td>
<td>70</td>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Renal vascular disease due to malignant hypertension</td>
<td>71</td>
<td>IV</td>
<td></td>
</tr>
<tr>
<td>Renal vascular disease due to hypertension</td>
<td>72</td>
<td>IV</td>
<td></td>
</tr>
<tr>
<td>Renal vascular disease due to polyarteritis</td>
<td>73</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Wegener's granulomatosis</td>
<td>74</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Glomerulonephritis related to liver cirrhosis</td>
<td>76</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Cryoglobulinaemic glomerulonephritis</td>
<td>78</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Renal vascular disease - due to other cause (not given above and not code 84-88)</td>
<td>79</td>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Diabetes glomerulosclerosis or diabetic nephropathy - Type I</td>
<td>80</td>
<td>VI</td>
<td></td>
</tr>
<tr>
<td>Diabetes glomerulosclerosis or diabetic nephropathy - Type II</td>
<td>81</td>
<td>VI</td>
<td></td>
</tr>
<tr>
<td>Myelomatosis/light chain deposit disease</td>
<td>82</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Amyloid</td>
<td>83</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Lupus erythematosus</td>
<td>84</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Henoch-Schoenlein purpura</td>
<td>85</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Goodpasture's Syndrome</td>
<td>86</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Systemic sclerosis (scleroderma)</td>
<td>87</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Haemolytic Uraemic Syndrome (including Moschcowitz Syndrome)</td>
<td>88</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Multi-system disease - other (not mentioned above)</td>
<td>89</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Tubular necrosis (irreversible) or cortical necrosis (different from 88)</td>
<td>90</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>91</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Gout</td>
<td>92</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Nephrocalcinosis and hypercalcaemic nephropathy</td>
<td>93</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Balkan nephropathy</td>
<td>94</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Kidney tumour</td>
<td>95</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Traumatic or surgical loss of kidney</td>
<td>96</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Other identified renal disorders</td>
<td>99</td>
<td>VII</td>
<td></td>
</tr>
<tr>
<td>Chronic renal failure; aetiology uncertain</td>
<td>00</td>
<td>VIII</td>
<td></td>
</tr>
</tbody>
</table>

I.  Glomerulonephritis/sclerosis;  
II.  Pyelonephritis;  
III.  Polycystic kidneys, adult type;  
IV.  Hypertension;  
V.  Renal vascular disease;  
VI.  Diabetes mellitus;  
VII.  Miscellaneous;  
VIII.  Unknown.